AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO025210211
Submit to EJMO
Cite this article
5
Download
44
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
EDITORIAL

Targeted immune cells: A fresh approach to treating atherosclerosis

Yi Chen1 ,  Yuhao Feng2 ,  Limei Qiu1 ,  Xianbin Kong3,4*
Show Less
1 College of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
2 College of Culture and Health Communication, Tianjin University of Traditional Chinese Medicine, Tianjin, China
3 College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
4 Tianjin Key Laboratory of Modern Chinese Medicine Theory of Innovation and Application, Tianjin University of Traditional Chinese Medicine, Tianjin, China
EJMO, 025210211 https://doi.org/10.36922/EJMO025210211
Received: 22 May 2025 | Accepted: 4 July 2025 | Published online: 22 July 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Download PDF
Cite
XML
Conflict of interest
Xianbin Kong is an Editorial Board Member of this journal. All authors declare no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
  1. Nie H, Yan C, Zhou W, Li TS. Analysis of immune and inflammation characteristics of atherosclerosis from different sample sources. Oxid Med Cell Longev. 2022;2022:5491038. doi: 10.1155/2022/5491038

 

  1. Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589-610. doi: 10.1038/s41573-021-00198-1

 

  1. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: Implications for vaccine development. Arterioscler Thromb Vasc Biol. 2005;25(1):18-28. doi: 10.1161/01.ATV.0000149142.42590.a2

 

  1. Depuydt MAC, Schaftenaar FH, Prange KHM, et al. Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells. Nat Cardiovasc Res. 2023;2(2):112-125. doi: 10.1038/s44161-022-00208-4

 

  1. Wang Y, Li W, Zhao T, et al. Interleukin-17-producing CD4+ t cells promote inflammatory response and foster disease progression in hyperlipidemic patients and atherosclerotic mice. Front Cardiovasc Med. 2021;8:667768. doi: 10.3389/fcvm.2021.667768

 

  1. Yang G, Qiu Y. Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. Medicine (Baltimore). 2023;102(6):e32384. doi: 10.1097/MD.0000000000032384

 

  1. Slutter B, Ley K. Editorial: Adaptive immunity in atherosclerosis. Front Immunol. 2024;15:1440283. doi: 10.3389/fimmu.2024.1440283

 

  1. Khambhati J, Engels M, Allard-Ratick M, Sandesara PB, Quyyumi AA, Sperling L. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Atherosclerosis. 2018;276:1-9. doi: 10.1016/j.atherosclerosis.2018.07.007

 

  1. Mushenkova NV, Bezsonov EE, Orekhova VA, Popkova TV, Starodubova AV, Orekhov AN. Recognition of oxidized lipids by macrophages and its role in atherosclerosis development. Biomedicines. 2021;9(8):915. doi: 10.3390/biomedicines9080915

 

  1. Fang F, Ni Y, Yu H, et al. Inflammatory endothelium-targeted and cathepsin responsive nanoparticles are effective against atherosclerosis. Theranostics. 2022;12(9):4200-4220. doi: 10.7150/thno.70896

 

  1. Distasio N, Dierick F, Ebrahimian T, Tabrizian M, Lehoux S. Design and development of branched poly(ss-aminoester) nanoparticles for interleukin-10 gene delivery in a mouse model of atherosclerosis. Acta Biomater. 2022;143:356-371. doi: 10.1016/j.actbio.2022.02.043

 

  1. Banka AL, Guevara MV, Brannon ER, et al. Cargo-free particles divert neutrophil-platelet aggregates to reduce thromboinflammation. Nat Commun. 2023;14(1):2462. doi: 10.1038/s41467-023-37990-z

 

  1. Engelen SE, Robinson AJB, Zurke Y, Monaco C. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: How to proceed? Nat Rev Cardiol. 2022;19(8):522-542. doi: 10.1038/s41569-021-00668-4

 

  1. May LT, Bartolo BA, Harrison DG, et al. Translating atherosclerosis research from bench to bedside: Navigating the barriers for effective preclinical drug discovery. Clin Sci (Lond). 2022;136(23):1731-1758. doi: 10.1042/CS20210862

 

  1. Shakeri A, Wang Y, Zhao Y, et al. Engineering organ-on-a-chip systems for vascular diseases. Arterioscler Thromb Vasc Biol. 2023;43(12):2241-2255. doi: 10.1161/ATVBAHA.123.318233

 

  1. Winkels H, Wolf D. Heterogeneity of t cells in atherosclerosis defined by single-cell RNA-sequencing and cytometry by time of flight. Arterioscler Thromb Vasc Biol. 2021;41(2):549-563. doi: 10.1161/ATVBAHA.120.312137

 

  1. Klumper N, Saal J, Berner F, et al. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. J Immunother Cancer. 2022;10(3):e004024. doi: 10.1136/jitc-2021-004024

 

  1. Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020;127(4):553-570. doi: 10.1161/CIRCRESAHA.120.316242

 

  1. Gong B, Guo Y, Li Y, et al. Immune checkpoint inhibitors in cancer: The increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium. BMC Med. 2024;22(1):44. doi: 10.1186/s12916-024-03261-x

 

  1. Ait-Oufella H, Lavillegrand JR, Tedgui A. Regulatory t cell-enhancing therapies to treat atherosclerosis. Cells. 2021;10(4):723. doi: 10.3390/cells10040723

 

  1. Wang L, Gao B, Wu M, Yuan W, Liang P, Huang J. Profiles of immune cell infiltration in carotid artery atherosclerosis based on gene expression data. Front Immunol. 2021;12:599512. doi: 10.3389/fimmu.2021.599512
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept